Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience

被引:0
作者
Francesco M. Minuto
Eugenia Resmini
Mara Boschetti
Alberto Rebora
Laura Fazzuoli
Marica Arvigo
Massimo Giusti
Diego Ferone
机构
[1] University of Genova,Department of Endocrine and Medical Sciences
[2] University of Genova,Center of Excellence for Biomedical Research
来源
Pituitary | 2012年 / 15卷
关键词
Acromegaly; OGTT; Growth hormone; IGF-I;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of this study is to assess the secretory pattern of GH after Oral Glucose Tolerance Test (OGTT) or day-curve (DC), in relation with IGF-I and to evaluate the influence of therapy on OGTT. A retrospective analysis in 279 OGTTs performed in 93 acromegalic patients in our unit from January 1988 to December 2005, in 77 patients also DC data were retrived. GH concentration was evaluated by 3 different systems (RIA, IRMA and chemiluminescence assays), and IGF-I by two RIAs. About 12% of OGTT samples were discordant with the baseline, while discordance between nadir and 120th minute was much lower (5%), with all discordant values, except one, near the cut-off lines. Correlation between DC and OGTT data was around 0.99 among all values, discordance rate between nadir and minimum DC was much lower than that with mean DC. In almost 80% of cases there was a complete concordance between OGTT and DC results, and in about 30% IGF-I was discordant with GH. Correlation analysis between IGF-I and GH was highest with DC data and lowest with OGTT baseline (T0). Considering different treatments discrepancy rates between GH and IGF-I were comparable. The best GH parameter is the minimum GH DC, although in the clinical practice the evaluation of OGTT GH in association with IGF-I is the most practical approach. In this case, the basal and T120 GH values can replace multiple sampling. Different treatment modalities do not influence the discordance rate between GH and IGF-I.
引用
收藏
页码:215 / 221
页数:6
相关论文
共 117 条
[1]  
Melmed S(2006)Medical progress: acromegaly N Engl J Med 355 2558-2573
[2]  
Alexander L(1980)Epidemiology of acromegaly in the Newcastle region Clin Endocrinol (Oxf) 12 71-79
[3]  
Appleton D(1988)Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984 Acta Med Scand 223 327-335
[4]  
Hall R(2004)Systemic complications of acromegaly: epidemiology, pathogenesis, and management Endocr Rev 25 102-152
[5]  
Ross WM(1999)Epidemiology of acromegaly Pituitary 2 29-41
[6]  
Wilkinson R(2004)Factors influencing mortality in acromegaly J Clin Endocrinol Metab 89 667-674
[7]  
Bengtsson BA(2005)IGF-I and mortality in patients with acromegaly J Endocrinol Invest 28 78-80
[8]  
Eden S(2000)Criteria for cure of acromegaly: a consensus statement J Clin Endocr Metab 85 526-529
[9]  
Ernest I(2002)Editorial: acromegaly–consensus, what consensus? J Clin Endocrinol Metab 87 3534-3536
[10]  
Oden A(2011)Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays Clin Chem 57 555-559